ArticleChemistry & biodiversity2025
Pharmacokinetic Prediction and Cytotoxicity of New Quercetin Derivatives.
Article in Chemistry & biodiversity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Comparative Effects of Quercetin and its α- and β-D-glucoside Derivatives in LPS-Stimulated C6 Astroglial Cells.Neurochemical research · 2026Article
- Integrated Phytochemical and Pharmacological Insights intoPlants (Basel, Switzerland) · 2026Review
- Quercetin as a multi-targeted therapeutic candidate in oral cancers: molecular mechanisms and preclinical evidence.Molecular biology reports · 2026Review
- Phytochemicals and REDOX Modulation: Molecular Mechanisms, Clinical Relevance, and Therapeutic Perspectives.Antioxidants (Basel, Switzerland) · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Quercetin (QUE) possesses various pharmacological properties; however, its low bioavailability and solubility hinder its beneficial effects. Enzymatic glycosylation has been explored to improve these aspects. In the present study, we used a sucrose phosphorylase variant to catalyze the regioselective transglucosylation of QUE, predicted the pharmacokinetic properties and toxicity of these molecules using in silico tools, and evaluated their cytotoxicity compared to the original molecule and a β-glucosylated derivative of QUE. Three α-glucosylated derivatives were obtained, which demonstrated improved pharmacokinetics, including a higher volume of distribution and lower clearance rate, with minimal likelihood of cytochrome P450 enzyme inhibition compared to QUE. QUE and the β-glucosylated derivative exhibited cytotoxicity in both cell types evaluated, whereas their α-glucosylated derivatives were nontoxic. The results presented provide an insight into the predicted behavior of these molecules in the body and, combined with cytotoxicity evaluation, will serve as a foundation for investigating the biological effects and mechanisms of action of these new molecules.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.